Top

Osteoporosis International

Published in:

01-11-2019 | Bisphosphonate | Original Article

What information can the lay public find about osteoporosis treatment? A descriptive study coding the content and quality of bisphosphonate information on the internet

Authors: L. N. Fuzzell, M. J. Richards, L. Fraenkel, S. L. Stark, M. C. Politi

Published in: Osteoporosis International | Issue 11/2019

Abstract

Summary

Despite its effectiveness, bisphosphonate use for osteoporosis is low. We assessed bisphosphonate information on the internet and found the most commonly listed benefits/risks were bone density loss, gastrointestinal issues, and jaw necrosis, that risk quantification was rare, and information quality varied. Findings underscore the importance of clinical communication about bisphosphonates.

Introduction

The US Preventative Services Task Force recommends osteoporosis screening and treatment with bisphosphonates in high-risk populations. However, bisphosphonate use among individuals with osteoporosis remains low. The content and quality of information from outside sources may influence individuals’ bisphosphonate decisions. Therefore, we sought to assess the content and quality of osteoporosis treatment information available to the public by conducting an internet search and coding available bisphosphonate information.

Methods

Eleven search terms about osteoporosis and bisphosphonates were entered into four search engines. Two raters assessed websites for information about bisphosphonates, whether and how benefits and side effects were described and quantified, contraindications, and dosing instructions. Coders also assessed website interface and slant/balance of information.

Results

One thousand four hundred seventy-three websites were identified. Two hundred twenty-seven websites met inclusion criteria and were coded. The most common bisphosphonate benefit described was prevention of bone density loss (77.1% of websites). The most common side effects described were gastrointestinal problems (66.1%) and jaw osteonecrosis (58.6%). Most websites did not quantify bisphosphonate benefits (78.0%) or side effects (82.4%). Complementary/integrative health websites (p < .001) and pharmaceutical litigation websites (p < .001) were more often slanted against taking bisphosphonates, compared to all websites coded. General medical knowledge websites were more balanced than other websites (p = .023).

Conclusions

The quality of bisphosphonate information on the internet varies substantially. Providers counseling patients about osteoporosis treatment should inquire about patients’ baseline bisphosphonate knowledge. Providers can complement accurate information and address potential bisphosphonate misconceptions.

Available only for authorised users

Wright Nicole C, Looker Anne C, Saag Kenneth G, Curtis Jeffrey R, Delzell Elizabeth S, Randall Susan, Dawson-Hughes Bess. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014;29(11):2520–2526. https://doi.org/10.1002/jbmr.2269

Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9(8):1137–1141. https://doi.org/10.1002/jbmr.5650090802 CrossRefPubMed

Bentler SE, Liu L, Obrizan M, Cook EA, Wright KB, Geweke JF, Chrischilles EA, Pavlik CE, Wallace RB, Ohsfeldt RL, Jones MP, Rosenthal GE, Wolinsky FD (2009) The aftermath of hip fracture: discharge placement, functional status change, and mortality. Am J Epidemiol 170(10):1290–1299. https://doi.org/10.1093/aje/kwp266 CrossRefPubMedPubMedCentral

Watts NB (2001) Osteoporotic vertebral fractures. Neurosurg Focus 10:3CrossRef

Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW, Kemper AR, Kubik M (2018) Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement. JAMA 319(24):2521–2531CrossRefPubMed

Qaseem A, Forciea MA, McLean RM, Denberg TD, for the Clinical Guidelines Committee of the American College of Physicians (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166(11):818. https://doi.org/10.7326/M15-1361 CrossRefPubMed

Cosman F, de Beur SJ, MS LB, Lewiecki EM, Tanner B, Randall S, Lindsay R et al (2014) Osteoporos Int 25(10):2359–2381. https://doi.org/10.1007/s00198-014-2794-2 CrossRefPubMedPubMedCentral

Eriksen EF, Díez-Pérez A, Boonen S (2014) Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 58:126–135. https://doi.org/10.1016/j.bone.2013.09.023 CrossRefPubMed

Adler RA, Fuleihan GE-H, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R, Pignolo RJ, Sellmeyer DE (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31(1):16–35. https://doi.org/10.1002/jbmr.2708 CrossRefPubMed

10.

Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85(11):4118–4124. https://doi.org/10.1210/jcem.85.11.6953 CrossRefPubMed

11.

Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, Kahwati LC (2018) Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the Us Preventive Services Task Force. JAMA 319(24):2532–2551. https://doi.org/10.1001/jama.2018.6537 CrossRefPubMed

12.

Farley JF, Blalock SJ (2009) Trends and determinants of prescription medication use for treatment of osteoporosis. Am J Health Syst Pharm 66(13):1191–1201. https://doi.org/10.2146/ajhp080248 CrossRefPubMed

13.

Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD (2014) Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res 29(9):1929–1937. https://doi.org/10.1002/jbmr.2202 CrossRefPubMed

14.

Jha S, Wang Z, Laucis N, Bhattacharyya T (2015) Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996–2012: an ecological analysis. J Bone Miner Res 30(12):2179–2187. https://doi.org/10.1002/jbmr.2565 CrossRefPubMed

15.

Cramer JA, Amonkar MM, Hebborn A, Altman R (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21(9):1453–1460. https://doi.org/10.1185/030079905X61875 CrossRefPubMed

16.

Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17(6):922–928. https://doi.org/10.1007/s00198-006-0085-2 CrossRefPubMed

17.

Sale JE, Gignac MA, Hawker G, Frankel L, Beaton D, Bogoch E, Elliot-Gibson V (2011 [cited 2018 Jun 7]) Decision to take osteoporosis medication in patients who have had a fracture and are “high” risk for future fracture: a qualitative study. BMC Musculoskelet Disord 12(1). https://doi.org/10.1186/1471-2474-12-92

18.

Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Poznak CHV, Watts N, Woo S-B, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22(10):1479–1491. https://doi.org/10.1359/jbmr.0707onj]

19.

Lewiecki EM (2010) Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom 13(4):335–345. https://doi.org/10.1016/j.jocd.2010.06.005 CrossRefPubMed

20.

Amante DJ, Hogan TP, Pagoto SL, English TM, Lapane KL (2015 [cited 2018 Sep 6]) Access to care and use of the Internet to search for health information: results from the US National Health Interview Survey. J Med Internet Res 17(4)

21.

Hong YA, Cho J (2017) Has the digital health divide widened? Trends of health-related internet use among older adults from 2003 to 2011. J Gerontol B Psychol Sci Soc Sci 72(5):856–863. https://doi.org/10.1093/geronb/gbw100 CrossRefPubMed

22.

Peterson G, Aslani P, Williams KA (2003) How do consumers search for and appraise information on medicines on the Internet? A qualitative study using focus groups. J Med Internet Res 5(4):e33. https://doi.org/10.2196/jmir.5.4.e33 CrossRefPubMedPubMedCentral

23.

Dunne SS, Dunne CP (2015) What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs. BMC Med 13(1):173. https://doi.org/10.1186/s12916-015-0415-3 CrossRefPubMedPubMedCentral

24.

Van Deursen AJ, Van Dijk JA (2009) Using the Internet: skill related problems in users’ online behavior. Interact Comput 21(5–6):393–402CrossRef

25.

Joseph-Williams N, Newcombe R, Politi M, Durand M-A, Sivell S, Stacey D, O’Connor A, Volk RJ, Edwards A, Bennett C (2014) Toward minimum standards for certifying patient decision aids: a modified Delphi consensus process. Med Decis Mak 34(6):699–710CrossRef

26.

Fagerlin A, Zikmund-Fisher BJ, Ubel PA (2011) Helping patients decide: ten steps to better risk communication. J Natl Cancer Inst 103(19):1436–1443CrossRefPubMedPubMedCentral

27.

O’Connor AM, Cranney A. User manual—acceptability [document on the Internet] [Internet]. Ottawa: Ottawa Hospital Research Institute; 2002 [cited 2018 Jul 10]. Available from: http://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Acceptability.pdf

28.

Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clinic Proceedings Elsevier 84:632–638CrossRef

29.

Cryer B, Bauer DC (2002) Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77(10):1031–1043. https://doi.org/10.4065/77.10.1031 CrossRefPubMed

30.

Trevena LJ, Zikmund-Fisher BJ, Edwards A, Gaissmaier W, Galesic M, Han PK, King J, Lawson ML, Linder SK, Lipkus I, Ozanne E, Peters E, Timmermans D, Woloshin S (2013) Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers. BMC Med Inform Decis Mak 13(2):S7. https://doi.org/10.1186/1472-6947-13-S2-S7 CrossRefPubMedPubMedCentral

31.

Lewiecki EM, Rudolph LA, Kiebzak GM, Chavez JR, Thorpe BM (2006) Assessment of osteoporosis-website quality. Osteoporos Int 17(5):741–752. https://doi.org/10.1007/s00198-005-0042-5 CrossRefPubMed

32.

Joshi A, Bhangoo RS, Kumar K (2011) Quality of nutrition related information on the internet for osteoporosis patients: a critical review. Technol Health Care 19(6):391–400. https://doi.org/10.3233/THC-2011-0643 CrossRefPubMed

33.

Pérez-López FR, Roncero GRP (2006) Assessing the content and quality of information on the treatment of postmenopausal osteoporosis on the World Wide Web. Gynecol Endocrinol 22(12):669–675. https://doi.org/10.1080/09513590601012603 CrossRefPubMed

34.

Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377(9773):1276–1287. https://doi.org/10.1016/S0140-6736(10)62349-5 CrossRefPubMedPubMedCentral

Title: What information can the lay public find about osteoporosis treatment? A descriptive study coding the content and quality of bisphosphonate information on the internet
Authors: L. N. Fuzzell
M. J. Richards
L. Fraenkel
S. L. Stark
M. C. Politi
Publication date: 01-11-2019
Publisher: Springer London
Keywords: Bisphosphonate
Osteonecrosis
Osteoporosis
Osteoporosis
Published in: Osteoporosis International / Issue 11/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-019-05008-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

What information can the lay public find about osteoporosis treatment? A descriptive study coding the content and quality of bisphosphonate information on the internet

Abstract

Summary

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2019

Prediction of lumbar vertebral strength of elderly men based on quantitative computed tomography images using machine learning

Effects of milk powder intervention on bone mineral density and indicators related to bone metabolism in Chinese adolescents

Laboratory evaluation of secondary causes of bone loss in Veterans with spinal cord injury and disorders

FRAX-based intervention and assessment thresholds for osteoporosis in Iran

Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes

Different surgical outcomes in a patient with bilateral atypical femoral fracture related to bisphosphonate use with or without teriparatide treatment